---
title: "RNXT.US (RNXT.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/RNXT.US/news.md"
symbol: "RNXT.US"
name: "RNXT.US"
parent: "https://longbridge.com/en/quote/RNXT.US.md"
datetime: "2026-05-20T05:42:22.801Z"
locales:
  - [en](https://longbridge.com/en/quote/RNXT.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/RNXT.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/RNXT.US/news.md)
---

# RNXT.US (RNXT.US) — Related News

### [RenovoRx Earnings Call Signals Commercial Inflection](https://longbridge.com/en/news/286979897.md)
*2026-05-20T00:16:23.000Z*
> RenovoRx, Inc. reported record Q1 2026 revenue of $563,000, marking a 136% sequential growth. The company highlighted st

### [RenovoRx Reports Q1 2026 Results: Full Earnings Call Transcript](https://longbridge.com/en/news/286468960.md)
*2026-05-14T21:04:07.000Z*
> RenovoRx (NASDAQ:RNXT) reported Q1 2026 revenue of $563,000, a 136% increase from Q4 2025, accounting for over half of t

### [RenovoRx | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 563 K](https://longbridge.com/en/news/286464035.md)
*2026-05-14T20:31:37.000Z*
### [RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP™ Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting](https://longbridge.com/en/news/283836521.md)
*2026-04-23T12:32:18.000Z*
> An abstract submission has been accepted as a sub-study within RenovoRx’s Phase III TIGeR-PaC clinical trial. This abstr

### [RenovoRx Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026 | RNXT Stock News](https://longbridge.com/en/news/281410663.md)
*2026-04-01T10:21:18.000Z*
> RenovoRx Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026 | RNXT Stock News

### [RenovoRx FY25 Net Loss Widens; Expects Completing Enrolment For Phase III TIGeR-PaC In Mid 2026](https://longbridge.com/en/news/281137471.md)
*2026-03-31T06:50:19.000Z*
> RenovoRx, Inc. reported a widened net loss of $11.2 million for FY25, up from $8.8 million, despite revenue growth to $1

### [RenovoRx Reports 2025 Results and Advances TIGeR-PaC Trial](https://longbridge.com/en/news/281085728.md)
*2026-03-30T22:52:37.000Z*
> RenovoRx Reports 2025 Results and Advances TIGeR-PaC Trial